Pharmac is proposing to fund two targeted combination treatments for people newly diagnosed with chronic lymphocytic leukaemia (CLL): venetoclax with ibrutinib, and venetoclax with obinutuzumab. If the proposal is approved, funding would start on 1 May 2026.

The change would make these combinations available as first treatment options. Venetoclax is currently funded with rituximab, as well as on its own, for CLL. Ibrutinib has been funded since 2022 for people whose CLL has returned or not responded to other treatments, and obinutuzumab has been funded with chlorambucil for some people with CLL since 2016.

“This proposal would give people access to powerful, targeted treatments immediately after their diagnosis,” Pharmac’s Director Pharmaceuticals, Adrienne Martin, said. Pharmac expects around 80–90 people a year to benefit over the next five years.

CLL is a slow‑growing blood cancer. Pharmac says using these medicines together earlier could help people achieve longer‑lasting remission, reduce the need for traditional chemotherapy, and mean fewer hospital visits.

Pharmac is seeking feedback from people with CLL, their whānau, health professionals, advocacy groups, and others. Consultation is open until 5pm, Wednesday 4 March. Submissions can be sent to consult@pharmac.govt.nz or made via the online form linked in the consultation.